S'abonner

Bacterial microbiota of the upper respiratory tract and childhood asthma - 19/04/17

Doi : 10.1016/j.jaci.2016.05.050 
Martin Depner, PhD a, , Markus J. Ege, MD a, b, Michael J. Cox, PhD c, Sarah Dwyer, PhD c, Alan W. Walker, PhD d, Lena T. Birzele a, Jon Genuneit, MD e, Elisabeth Horak, MD f, Charlotte Braun-Fahrländer, MD g, h, Hanna Danielewicz, MD, PhD i, Raina M. Maier, PhD j, Miriam F. Moffatt, PhD c, William O. Cookson, MD c, Dick Heederik, PhD k, Erika von Mutius, MD a, b, Antje Legatzki, PhD a
a Dr von Hauner Children's Hospital, LMU Munich, Munich, Germany 
b German Center for Lung Research (DZL), Munich, Germany 
c National Heart & Lung Institute, Imperial College London, London, United Kingdom 
d Pathogen Genomics Group, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom 
e Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany 
f Division of Cardiology and Pulmonology, Department of Pediatrics and Adolescents, Innsbruck Medical University, Innsbruck, Austria 
g Swiss Tropical and Public Health Institute, Basel, Switzerland 
h University of Basel, Basel, Switzerland 
i Department of Pediatrics, Allergology and Cardiology, Wroclaw Medical University, Wroclaw, Poland 
j Department of Soil, Water and Environmental Science, University of Arizona, Tucson, Ariz 
k Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, University of Utrecht, Utrecht, The Netherlands 

Corresponding author: Martin Depner, PhD, Dr von Hauner Children's Hospital, Lindwurmstrasse 4, 80337 Munich, Germany.Dr von Hauner Children's HospitalLindwurmstrasse 4Munich80337Germany

Abstract

Background

Patients with asthma and healthy controls differ in bacterial colonization of the respiratory tract. The upper airways have been shown to reflect colonization of the lower airways, the actual site of inflammation in asthma, which is hardly accessible in population studies.

Objective

We sought to characterize the bacterial communities at 2 sites of the upper respiratory tract obtained from children from a rural area and to relate these to asthma.

Methods

The microbiota of 327 throat and 68 nasal samples from school-age farm and nonfarm children were analyzed by 454-pyrosequencing of the bacterial 16S ribosomal RNA gene.

Results

Alterations in nasal microbiota but not of throat microbiota were associated with asthma. Children with asthma had lower α- and β-diversity of the nasal microbiota as compared with healthy control children. Furthermore, asthma presence was positively associated with a specific operational taxonomic unit from the genus Moraxella in children not exposed to farming, whereas in farm children Moraxella colonization was unrelated to asthma. In nonfarm children, Moraxella colonization explained the association between bacterial diversity and asthma to a large extent.

Conclusions

Asthma was mainly associated with an altered nasal microbiota characterized by lower diversity and Moraxella abundance. Children living on farms might not be susceptible to the disadvantageous effect of Moraxella. Prospective studies may clarify whether Moraxella outgrowth is a cause or a consequence of loss in diversity.

Le texte complet de cet article est disponible en PDF.

Key words : Asthma, childhood, upper respiratory tract, throat, nose, microbiota, 16S rRNA gene

Abbreviations used : GABRIELA, OTU, OR, qPCR, 16S rRNA


Plan


 This study was supported by the European Research Council (grant no. 250268) and the Wellcome Trust (grant no. 098051).
 Disclosure of potential conflict of interest: M. Depner receives grant support from the European Research Council and the German Research Foundation. M. J. Ege receives grant support from the European Research Council (grant no. 250268). J. Genuneit receives grant support from the European Commission (grant no. LSHB-CT-2006-018996). D. Heederik receives grant support from Utrecht University. E. von Mutius receives grant support from the European Research Council and the German Research Foundation; serves on the board for the American Academy of Allergy, Asthma & Immunology; serves as a consultant for System Analytic Ltd; provides expert testimony for University of Tampere, GBS RE HEFCE; receives payments for lectures from Ökosoziales Forum Oberösterreich, Mundipharma, HAL Allergie GmbH, DOC Congress SRL, American Thoracic Society, and Novartis Pharma; and receives personal fees from OM Pharma SA, AbbVie Deutschland GmbH & Co KG, and medUpdate GmbH. A. Legatzki receives grants from the European Research Council (grant no. 250268). The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  American Academy of Allergy, Asthma & Immunology. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 139 - N° 3

P. 826 - mars 2017 Retour au numéro
Article précédent Article précédent
  • Automated identification of an aspirin-exacerbated respiratory disease cohort
  • Katherine N. Cahill, Christina B. Johns, Jing Cui, Paige Wickner, David W. Bates, Tanya M. Laidlaw, Patrick E. Beeler
| Article suivant Article suivant
  • The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study
  • Tetyana Kendzerska, Teresa M. To, Shawn D. Aaron, M. Diane Lougheed, Mohsen Sadatsafavi, J. Mark FitzGerald, Andrea S. Gershon, Canadian Respiratory Research Network

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.